      Document 0207
 DOCN  DRG0207
 UNIQUE IDENTIFIER        DRG-0040
 NAME OF SUBSTANCE        Peptide T [Merck Index 1989]
 REGISTRY NUMBER          106362-33-8
 RELATED REGISTRY NUMBER  106362-32-7
 STANDARD CHEMICAL NAME   N-(N-(N(2)-(N-(N-(N-(N-D-alanyl-L-seryl)-
                          L-threonyl)-L-threonyl)-L-threonyl)-L-asparag-
                          inyl)- L-tyrosyl)-L-threonine [CHEMLINE]
 SYNONYMS                 D-Ala-1-Peptide-T-amide [NIMH 89 MH-SF]
 SYNONYMS                 HIV Peptide T [CHEMLINE]
 PROTOCOL ID NUMBERS      NIMH 89 MH-SF
 PROTOCOL ID NUMBERS      NIMH 89 MH-28
 PROTOCOL ID NUMBERS      FDA 078A
 PROTOCOL ID NUMBERS      FDA 115A
 PROTOCOL ID NUMBERS      NIMH 90 OD-0013
 IND NUMBER               BB-2535
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: Blocks receptor for HIV in
                          the brain. Blocks viral entry by competing
                          for receptor sites on the CD4 molecule; HIV
                          attachment to human CD4+ lymphocytes and
                          brain cells appears to occur through this
                          polypeptide sequence. Peptide T and two
                          closely related analogs were found to exhibit
                          the ability to block HIV infection of human T
                          cells.  It was reported that Peptide T and
                          vasoactive intestinal peptide, a natural
                          hormone which normally interacts with CD4
                          receptors, can prevent gp120-induced neuronal
                          cell death in vitro. In a clinical trial with
                          6 AIDS patients with neuropsychiatric
                          disorders and 5 control subjects, serum
                          half-life of Peptide T was extended 4-4.5
                          hours and its concentration in cerebrospinal
                          fluid was 1/8 of achieved plasma levels; all
                          AIDS patients reported an increase in energy,
                          arithmetic concentration, logical memory, and
                          visuospatial processing. Increase in health
                          related quality of life due to fatigue
                          suppression has been reported in studies of
                          peptide T. [AmFAR Tx Dir Dec 1988] [Int Conf
                          AIDS. 1992 Jul 19-24;8(3): (abstract no PuB
                          7149)] [NIMH 89 MH-SF]
 DISEASES STUDIED/TREATED Primary HIV infection; studied as a treatment
                          for HIV associated neuropathy and
                          neuropsychiatric impairment [AmFAR Tx Dir
                          1995;7(4)]
 CLASSIFICATION CODE      Antiretroviral [Drug Evaluations Annual 1995]
 CLASSIFICATION CODE      Immunomodulator [NIMH 89 MH-28]
 ADVERSE EFFECTS          May cause rash and itching after several
                          weeks of treatment; no mucosal toxicity was
                          observed in AIDS patients during intranasal
                          administration of Peptide T. [AmFAR Tx Dir
                          Dec 1988]
 CONTRAINDICATIONS        Should not be used by pregnant women or by
                          patients having a long previous history of
                          psychiatric illness. [NIMH 89 MH-28]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Synthetic hydrophilic
                          octapeptide (ASTTTNYT) [AmFAR Tx Dir Dec
                          1988]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Octapeptide sequence of HIV
                          envelope gp120; named peptide T because of
                          high threonine content [Merck Index 1989]
 CHEMICAL/PHYSICAL DATA   MOLECULAR FORMULA: C35H55N9O16 [Merck Index
                          1989]
 CHEMICAL/PHYSICAL DATA   MOLECULAR WEIGHT: 857.87 [Merck Index 1989]
 CHEMICAL/PHYSICAL DATA   PHYSICAL DESCRIPTION: Powder [NIMH 89 MH-SF]
                          [NIMH 89 MH-28]
 CHEMICAL/PHYSICAL DATA   ELEMENTAL COMPOSITION: C49.00%, H6.46%,
                          N14.69%, O29.84% [Merck Index 1989]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: Sterile solution [NIMH 89 MH-28]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Subcutaneous
                          administration; intranasal administration.
                          [AmFAR Tx Dir 1993 April;6(3)]
 SUBSTANCE DELIVERY DATA  STORAGE: Stable in lyophilized state at room
                          temperature for greater than one week. [NIMH
                          89 MH-SF] [NIMH 89 MH-28]
 MANUFACTURERS            Bristol-Myers
 REFERENCES               MacFadden DK, Phipps DJ, Doob PR. Peptide T
                          immunomodulation: patient data. Int Conf
                          AIDS. 1993 Jun 6-1;9(1):496 (abstract no.
                          PO-B28-2164).
 REFERENCES               Johansson O, Hilliges M, Talme T, Marcusson
                          JA, Wetterberg L. Speculations around the
                          mechanism behind the action of peptide T in
                          the healing of psoriasis: a minireview. Acta
                          Derm Venereol. 1993 Dec;73(6):401-3.
 REFERENCES               MacFadden DK, Doob PR. Peptide T: onset of
                          action and palliation of symptoms with
                          peptide T in HIV-disease. Int Conf AIDS. 1992
                          Jul 19-24;8(3):103 (abstract no. PuB 7328).
 REFERENCES               Bridge P, Linde R, Ollo C, Eaton E, Parker E,
                          Mayer K, Heseltine P, Ruff M, Pert C. Peptide
                          T HIV-1 cognitive effects. Int Conf AIDS.
                          1992 Jul 19-24;8(2):B218 (abstract no. PoB
                          3765).
 REFERENCES               Bridge P, Linde R, Ollo C, Mayer K.
                          Neuropsychologic results of control HIV-1
                          trial of peptide T. Int Conf AIDS. 1991 Jun
                          16-21;7(2):79 (abstract no. TH.B.90).
 REFERENCES               MacFadden DK, Doob PR. Role of peptide T in
                          palliation of HIV-1-related painful
                          peripheral neuropathy. Int Conf AIDS. 1991
                          Jun 16-21;7(2):225 (abstract no. W.B.2173).
 REFERENCES               Bridge TP, Heseltine PN, Parker ES, Eaton EM,
                          Ingraham LJ, McGrail ML, Goodwin FK. Results
                          of extended peptide T administration in AIDS
                          and ARC patients. Psychopharmacol Bull.
                          1991;27(3):237-45.
 REFERENCES               Heseltine P, Eaton E, Buchsbaum M, Parker E,
                          McGrail M, Leedom J, Bridge P. Effect of
                          peptide T on AIDS dementia complex (ADC):
                          correlation of PET scans and cognitive
                          domains. Int Conf AIDS. 1991 Jun
                          16-21;7(1):183 (abstract no. M.B.2006).
 REFERENCES               Ruff MR, Smith C, Kingan T, Jaffe H,
                          Heseltine P, Gill MA, Mayer K, Pert CB,
                          Bridge TP. Pharmacokinetics of peptide T in
                          patients with acquired immunodeficiency
                          syndrome (AIDS). Prog Neuropsychopharmacol
                          Biol Psychiatry. 1991;15(6):791-801.
 REFERENCES               Mayer K, Bridge P, Moon M, Linde R, Roffman
                          M. Phase I study of Intranasal peptide T:
                          clinical and lab results. Int Conf AIDS. 1990
                          Jun 20-23;(3):200 (abstract no. S.B.459).
 ENTRY MONTH              8906
 LAST REVISION DATE       960310
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
